PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while Healthcare median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Gross profit decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D change of 29.66% versus flat Healthcare spending. Walter Schloss would verify adequacy.
16.61%
G&A change of 16.61% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Operating expenses growth exceeding 1.5x Healthcare median of 2.65%. Jim Chanos would check for waste.
25.48%
Total costs growth exceeding 1.5x Healthcare median of 2.54%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth exceeding 1.5x Healthcare median of 0.90%. Jim Chanos would check for overinvestment.
-28.10%
EBITDA decline while Healthcare median is -1.08%. Seth Klarman would investigate causes.
-46.25%
EBITDA margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-27.47%
Operating income decline while Healthcare median is -2.57%. Seth Klarman would investigate causes.
-45.52%
Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-14.81%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-27.92%
Pre-tax income decline while Healthcare median is -1.10%. Seth Klarman would investigate causes.
-46.04%
Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Net income decline while Healthcare median is -2.02%. Seth Klarman would investigate causes.
-46.04%
Net margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-20.00%
EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-20.00%
Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
6.47%
Share count reduction below 50% of Healthcare median of 0.20%. Jim Chanos would check for issues.
6.47%
Diluted share reduction below 50% of Healthcare median of 0.19%. Jim Chanos would check for issues.